Literature DB >> 8616767

Distant metastasis from bilharzial bladder cancer.

M S Zaghloul1.   

Abstract

BACKGROUND: Distant metastasis is rarely described among bilharzial bladder cancer patients. However, with improved 5-year survival rates following adjuvant local therapy, distant metastasis is now reported with increasing frequency.
METHODS: Three-hundred-fifty-seven bilharzial bladder cancer patients were treated at the National Cancer Institute in Cairo, Egypt, during the period 1981-1990. They were treated with either cystectomy alone, cystectomy preceded by a short course of preoperative radiotherapy (2000 cGy/5 fractions/1 week), or cystectomy followed by postoperative irradiation (5000 cGy/25 fractions/5 weeks or 3750 cGy/30 fractions/2 weeks). These patients were retrospectively analyzed.
RESULTS: The overall 5-year actuarial rate of distant metastasis was 23% (95% confidence interval, 21-25%), which was essentially the same in the 3 therapeutic groups. Both univariate and multivariate analyses revealed that the independent risk factors for distant metastasis were pelvic lymph node involvement (P = 0.005), pathologic stage (P = 0.004), and histopathologic grade (P = 0.05). Histologic type and local pelvic recurrence appeared in the univariate analysis as working risk factors; however, they were proven by multivariate analysis to be dependent on other risk factors. Patients who had none of the independent risk factors had a lower rate of distant metastasis (II%) and a high local control rate (88%). Those who had more than one risk factor had high distant metastasis rate (51%) and low local control rate (41%), regardless of the therapeutic modality used. The identified independent risk factors determined both the distant metastasis and the local control rates.
CONCLUSIONS: Unlike previous reports, this rigorous study of distant metastasis in bilharzial bladder cancer revealed an occurrence rate of 23%. This high rate was associated with pelvic lymph node involvement, pathologic stage, and histopathologic grade. Histologic type, local pelvic recurrence, or the addition of pre- or post-operative radiotherapy proved not to be independent risk factors.

Entities:  

Mesh:

Year:  1996        PMID: 8616767     DOI: 10.1002/(sici)1097-0142(19960215)77:4<743::aid-cncr21>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.

Authors:  Mohamed S Zaghloul; Rimoun Boutrus; Hisham El-Hossieny; Yasser Abdel Kader; Inas El-Attar; Mohamed Nazmy
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

Review 2.  Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Authors:  Rosa Nadal; Andrea B Apolo
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 3.  Schistosomiasis and cancer in egypt: review.

Authors:  Hussein Khaled
Journal:  J Adv Res       Date:  2013-06-26       Impact factor: 10.479

4.  Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.

Authors:  Valérie Fonteyne; Piet Dirix; Sara Junius; Elke Rammant; Piet Ost; Gert De Meerleer; Martijn Swimberghe; Karel Decaestecker
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.